What question did this study set out to answer?

December 8, 2025BloodOpen Access

Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

HXHongyun Xing

Discussion

Member takes

Implication

Clinical analysis shows 100% response rate with zanubrutinib, rituximab, and high-dose methotrexate for CNS DLBCL, indicating strong anti-tumor activity and manageable adverse events.

Key Points

To investigate the efficacy and safety of zanubrutinib combined with rituximab and high-dose methotrexate in treating CNS DLBCL.
Analyzed clinical data from patients with CNS DLBCL treated with zanubrutinib, rituximab, and high-dose methotrexate.
Included 7 patients, median age 51, with various gene mutations.
Evaluated efficacy using PET/CT after at least 2 treatment cycles.
100% objective response rate observed in all patients.
85.7% achieved complete response, 14.3% achieved partial response.
Grade ≥ 3 hematological adverse events included neutropenia (57.1%) and thrombocytopenia (28.6%).

Cite This Study

Hongyun Xing (2025) studied this question.

synapsesocial.com/papers/69362f514fa91c937236d906 https://doi.org/10.1182/blood-2025-7224

View Full Paper

Ask AI

Bookmark

Implication

Clinical analysis shows 100% response rate with zanubrutinib, rituximab, and high-dose methotrexate for CNS DLBCL, indicating strong anti-tumor activity and manageable adverse events.

Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Efficacy and Safety of Zanubrutinib Combined with Rituximab and High-Dose Methotrexate in the Treatment of Central Nervous System Diffuse Large B-Cell Lymphoma

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider